ALMR · Alamar Biosciences Inc.
AI read · Neutral
The AI's read
Alamar beat Q2 estimates, posted sales up 82% YoY, raised fiscal 2026 sales guidance, and expanded its Alzheimer’s partnership with Gates Ventures to add 86,000 samples. The combo is company-positive and supports a longer-term data moat. The market already hugged the headline. ALMR jumped ~33.9%, sits near its 52-week high, and RSI is 80.06, so much of the good news looks priced. We lean neutral. The fundamental update matters, but the technical stretch and large intraday pop leave limited asymmetric upside versus downside from here.